Toggle light / dark theme

A pro-oxidant combination of resveratrol and copper down-regulates multiple biological hallmarks of ageing and neurodegeneration in mice

ROS are short lived molecular species containing an unpaired electron which makes them highly reactive as they search for another electron to pair with, and in the process can damage biomolecules such as DNA, proteins and lipids54. ROS induced oxidative stress is known to have multiple deleterious effects on host cells55. However, we have reported that, paradoxically, when ROS is artificially generated outside the cell in the extracellular spaces of the body, they can have wide ranging therapeutic effects18,19,20,26,27. Admixing R with Cu leads to generation of oxygen radicals by virtue of the ability of R to reduce Cu (II) to Cu (I)23,25. Oxygen radicals that are generated in the stomach upon oral administration of R–Cu are apparently absorbed to have systemic effects in the form of deactivation/eradication of extracellular cfChPs. We have shown that cfChPs have wide-ranging damaging effects on host cells. For example, cfChPs can readily enter into the healthy cells to damage their DNA, activate inflammatory cytokines and promote apoptosis via the mitochondrial pathway13,14. Given that 1 × 109–1 × 1012 cells die in the body every day56,57, we have hypothesised that repeated and lifelong assault on healthy cells by cfChPs derived from the dying cells may be the underlying cause of ageing15,16. In support of this hypothesis we show in this article that prolonged oral administration of R–Cu to ageing mice down-regulated multiple biological hallmarks of ageing and neurodegeneration by virtue of its ability to deactivate cfChPs. Our results suggest that R–Cu may qualify as an ideal anti-ageing agent since it has the potential to simultaneously retard or delay the many conditions that are associated with ageing2. To be globally applicable, an ideal anti-ageing agent should also be inexpensive and non-toxic—the two criteria that are also met by R–Cu. The latter can be easily administered orally, and both R and Cu are already approved for human use. An illustrated summary of the study design and the mechanisms by which R–Cu generated oxygen radicals eradicate cfChPs from brain micro-environment leading to down-regulation of ageing hallmarks is provided in Fig. 10.

The mechanism(s) by which R–Cu down-regulates the multiple biological hallmarks of ageing and neurodegeneration needs elaboration. Reversal of telomere shortening by R–Cu may suggest that telomere shortening could be a consequence of DNA damage inflicted by cfChPs which shear off telomere ends causing them to shorten. We observed differential effects between female and male mice with respect to telomere abnormalities. R–Cu effects in preventing telomere abnormalities in female mice were statistically significant for all parameters tested, while this was not the case in male mice. The biological explanation for this discrepant finding remains to be determined. Breakage of telomere ends may also help to explain our detection of persistent γ-H2AX signals in telomere regions of brain cells (DNA-SCARS)—an established signature of senescence43. The bare chromosomal ends can fuse with each other to lead to chromosomal instability and aneuploidy48, as was detected in our study.

That Our Body Has A MEMORY OF YOUTH Has Been Proved | Dr David Sinclair Interview Clips

Just a quick vid. He mentions the hope of replacing current gene therapy with a pill or three which I heard Cynthia Kenyon say many years ago.


Dr David Sinclair talks about longevity genes, genes therapies and his works on resetting the eyes in this short clip.

David Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study sirtuins—protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction—as well as chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, cancer, and cellular reprogramming.

Dr David Sinclair has suggested that aging is a disease—and that we may soon have the tools to put it into remission—and he has called for greater international attention to the social, economic and political and benefits of a world in which billions of people can live much longer and much healthier lives.

Dr David Sinclair is the co-founder of several biotechnology companies (Life Biosciences, Sirtris, Genocea, Cohbar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others.

New Protein Identified That May Contribute to Alzheimer’s Disease

Alzheimer’s disease (AD) is a debilitating progressive illness that begins with mild memory loss and slowly destroys cognitive function and memory. It currently has no cure and is predicted to affect over 100 million people worldwide by 2050. In the United States, AD is the leading cause of dementia in older adults and the 7th most common cause of death, according to the National Institute on Aging.

Ongoing Alzheimer’s research is focused on two key neurotoxic proteins: amyloid beta (Aβ) and tau. Although these proteins have been shown to be associated with AD, the levels of Aβ and tau do not consistently explain or correlate with the severity of cognitive decline for some people with the disease.

Investigators at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, set out to identify other proteins that may be directly involved with fundamental aspects of AD, like synaptic loss and neurodegeneration. They exposed laboratory neurons to human brain extracts from about 40 people who either had AD, were protected from AD despite having high Aβ and tau levels, or were protected from AD with little or no Aβ and tau in their brains.

Prof. Dr. Gordan Lauc, Ph.D. — Founder & CEO, Genos; CSO, GlycanAge; Advancing The Glycosciences

(http://www.pharma.unizg.hr/en/about-us/staff/gordan–lauc, 450.html) is Professor of Biochemistry and Molecular Biology at the University of Zagreb, Faculty of Pharmacy and Biochemistry, and Founder and CEO of Genos Ltd. (https://genos-glyco.com/), a research-intensive SME located in Zagreb, Croatia with core of expertise in molecular genetics and glycomics (The comprehensive study the entire complement of sugars, whether free or present in more complex molecules of an organism) and they perform contract research, contract analysis and service for numerous universities, hospitals and private individuals in Europe and overseas.

Prof. Dr. Lauc also is CSO of GlycanAge LTD (https://glycanage.com/), a company that has developed a ground-breaking test that analyses your personal glycobiome for insights in improving your health and monitoring your biological age, and Co-Director of the Human Glycome Project (https://human-glycome.org/).

Prof. Dr. Lauc graduated with a degree in molecular biology at the University of Zagreb Faculty of Science in 1992, and obtained Ph.D. in Biochemistry and the University of Zagreb in 1995. He got his postdoctoral training at the Institute for Medical Physics and Biophysics in Münster and Johns Hopkins University in Baltimore. Since 1993 he has been employed at the Faculty of Pharmacy and Biochemistry in Zagreb. Between 1998 and 2010 he was also part-time employed at the University of Osijek School of Medicine where he founded a DNA laboratory for the identification of war victims and also served as Vice-Dean for Science between 2001 and 2005.

Prof. Dr. Lauc is author of over 100 research papers published in international journals and six international patents. He was invited to lecture at numerous international conferences, elected for visiting professor at the Johns Hopkins University and in 2011 also inducted in the prestigious Johns Hopkins Society of Scholars. If 2012 he was appointed Honorary Professor at the University of Edinburgh and Adjunct Professor at the Edith Cowan University in Perth.

Prof. Dr. Lauc chaired a number of conferences, including the “European Science Foundation Exploratory Workshop on Glycoscience” which resulted in the creation of the “European Glycoscience Forum”.

Prof. Dr. Lauc was a chairman of the committee that prepared Croatian National Action plan for the increased investment in research in development (2007), and was a member of the National Science Council between 2009 and 2013 and also and President of the National Council for Natural Sciences. He is a President-elect of the International Glycoscience Organization and member of the Steering Committee of the European Glycoscience Forum.

Reincarnation and Robots with Ben Goertzel

Ben Goertzel, PhD, is author of many books on artificial intelligence including Ten Years to the Singularity if We Really Really Try; Engineering General Intelligence, Vols. 1 and 2; The Hidden Pattern: A Patternist Philosophy of Mind; and The Path to Posthumanity. He is also editor (with Damien Broderick) of an anthology about parapsychology titled, Evidence for Psi: Thirteen Empirical Research Reports. He is chief scientific officer for Hanson Robotics in Hong Kong.

Here he notes that, while the question of reincarnation in robots seems outlandish, most of our present technology would have seemed nonsensical and incomprehensible to earlier generations of humans. He quotes the 14th Dalai Lama who suggested (half-jokingly) that artificial intelligence programmers of the future might incarnate into robots. He cites Stephen Braude’s book, Immortal Remains, as demonstrating that we must consider some version of consciousness operating outside of the body. He outlines the sort of scientific and metaphysical models that might lead to such a development.

New Thinking Allowed host, Jeffrey Mishlove, PhD, is author of The Roots of Consciousness, Psi Development Systems, and The PK Man. Between 1986 and 2002 he hosted and co-produced the original Thinking Allowed public television series. He is the recipient of the only doctoral diploma in “parapsychology” ever awarded by an accredited university (University of California, Berkeley, 1980). He is also past-president of the non-profit Intuition Network, an organization dedicated to creating a world in which all people are encouraged to cultivate and apply their inner, intuitive abilities.

(Recorded on April 29, 2016)

Association between work characteristics and epigenetic age acceleration: cross-sectional results from UK — Understanding Society study

Occupation-related stress and work characteristics are possible determinants of social inequalities in epigenetic aging but have been little investigated. Here, we investigate the association of several work characteristics with epigenetic age acceleration (AA) biomarkers.

The study population included employed and unemployed men and women (n = 631) from the UK Understanding Society study. We evaluated the association of employment and work characteristics related to job type, job stability; job schedule; autonomy and influence at work; occupational physical activity; and feelings regarding the job with four epigenetic age acceleration biomarkers (Hannum, Horvath, PhenoAge, GrimAge) and pace of aging (DunedinPoAm, DunedinPACE).

We fitted linear regression models, unadjusted and adjusted for established risk factors, and found the following associations for unemployment (years of acceleration): HorvathAA (1.51, 95% CI 0.08, 2.95), GrimAgeAA (1.53, 95% CI 0.16, 2.90) and 3.21 years for PhenoAA (95% CI 0.89, 5.33). Job insecurity increased PhenoAA (1.83, 95% CI 0.003, 3.67), while working at night was associated with an increase of 2.12 years in GrimAgeAA (95% CI 0.69, 3.55). We found effects of unemployment to be stronger in men and effects of night shift work to be stronger in women.

/* */